Rare Diseases and Orphan Drugs

Tatjana Michel works with synthetic modified mRNA treatment strategy since 2013. Her work is focused on the development and evaluation of mRNA-based drugs for rare monogenetic diseases like alpha-1-antitrypsin deficiency or familial hypercholesterolemia. Prior to that, she worked on strategies for cell trans differentiation for heart regeneration and investigated immunogenic effects caused through synthetic nucleic acids